Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

35.440
+0.1400.40%
Volume:32.82M
Turnover:1.17B
Market Cap:146.65B
PE:39.97
High:36.400
Open:35.820
Low:35.220
Close:35.300
52wk High:44.000
52wk Low:16.200
Shares:4.14B
HK Float Shares:4.14B
Volume Ratio:0.78
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.887
ROE:10.50%
ROA:5.89%
PB:2.89
PE(LYR):39.97
PS:6.47

Loading ...

China stocks steady as metals rally counters consumer, AI losses

Reuters
·
Feb 11

BUZZ-WuXi Biologics climbs to 4-month high on robust earnings estimates

Reuters
·
Feb 11

BRIEF-Wuxi Biologics FY Revenue RMB21,790 Million

Reuters
·
Feb 11

WUXI BIO Issues Positive Profit Alert, Anticipates 46.3% Rise in Annual Shareholder Profit

Stock News
·
Feb 11

WuXi Biologics (Cayman) Inc. (Stock Code: 2269) Anticipates Notable Profits Growth for FY2025

Bulletin Express
·
Feb 11

WuXi Biologics (Cayman) Inc. (2269) Schedules Board Meeting to Review 2025 Annual Results

Bulletin Express
·
Feb 11

WuXi Biologics Board to Approve Annual Results

Reuters
·
Feb 11

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

Reuters
·
Feb 11

WuXi Biologics -FY Profit Expected to Increase to RMB5,733 Mln

THOMSON REUTERS
·
Feb 11

Biopharmaceutical Stocks Show Broad Gains with CSPC PHARMA Leading with Over 7% Rise

Deep News
·
Feb 10

CRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound

Stock News
·
Feb 10

Wuxi Biologics (Cayman) Stock Rises 1.5% in Hong Kong

Dow Jones
·
Feb 09

WuXi Biologics Receives EcoVadis Platinum Medal for Third Consecutive Year

Reuters
·
Feb 09

WuXi Biologics Alliances Deepen Role In Complex Autoimmune And Fusion Drugs

Simply Wall St.
·
Feb 06

Wuxi Biologics (Cayman) Stock Advances 2.6% in Hong Kong

Dow Jones
·
Feb 05

Wuxi XDC Cayman Inc. verschiebt Versand der Angebotsunterlagen

Reuters
·
Feb 04

TOT BIOPHARM Delays Dispatch of Composite Offer Document

Reuters
·
Feb 04

Assessing WuXi Biologics (SEHK:2269) Valuation After New Autoimmune And Biologics Collaboration Wins

Simply Wall St.
·
Feb 04

WuXi Biologics Signs License and Research Service Agreement with Vertex Pharmaceuticals

Reuters
·
Feb 03

WuXi Biologics schließt Lizenz- und Forschungsdienstleistungsvertrag mit Vertex Pharmaceuticals für T-Zell-Engager ab

Reuters
·
Feb 03